Group 1 - The core point of the article is the strategic cooperation between Hanyu Pharmaceutical and the digital asset platform KuCoin to explore the tokenization of "future revenue rights of innovative drug research and development" as a pilot project in Hong Kong [1] - The company is actively exploring innovative models based on its operational needs and appreciates suggestions regarding potential collaborations with major shareholders and other digital asset platforms [1]